Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brolucizumab - Novartis

Next Previous
X
Search
Drug Profile

Brolucizumab - Novartis

Alternative Names: Beobyu; BEOVU; Beovu; Brolucizumab-dbll; ESBA-1008; RTH-258

Latest Information Update: 01 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ESBATech
  • Developer Novartis
  • Class Antibodies; Eye disorder therapies; Immunoglobulin Fv fragments; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Wet age-related macular degeneration
  • Registered Diabetic macular oedema
  • Phase III Diabetic retinopathy; Polypoidal choroidal vasculopathy; Retinal vein occlusion

Most Recent Events

  • 27 Mar 2024 Pyxis Oncology sells the rights to royalties from the commercialization of brolucizumab to Novartis
  • 28 Feb 2024 Novartis completes the phase III trial in Wet age-related macular degeneration (Treatment-naive) in China (Intravitreous) (NCT04047472)
  • 23 Aug 2023 Apexigen has been acquired and merged into Pyxis Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top